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Summary Individuals with naevoid basal cell carcinoma (Gorlin) syndrome are at increased risk of developing medulloblastoma in childhood.
We have shown that approximately 5% of patients with Gorlin syndrome will develop this complication in the first few years of life, and
in addition 10% of patients with medulloblastoma diagnosed at age 2 years or under have Gorlin syndrome. One out of three
medulloblastomas occurring in patients with Gorlin syndrome was shown to have lost the wild-type allele on 9q, indicating that the Gorlin
locus probably acts as a tumour suppressor in the development of this tumour. We have also confirmed this role in a basal cell carcinoma
(BCC) from the same individual. Information from these families would suggest that Gorlin syndrome is more common than previously
recognized and may not always be diagnosed on clinical grounds alone even in middle life.
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The naevoid basal cell carcinoma (Gorlin) syndrome is a domi-
nantly inherited condition that has been localized to chromosome
9q by linkage analysis (Farndon et al, 1992). Affected individuals
are at increased risk of developing a number of tumours, most
notably multiple basal cell carcinomas (Gorlin, 1990; Evans et al,
1993). There are many reports of medulloblastoma occurring in
the context ofGorlin syndrome, and we recently reported the inci-
dence of this in a large population-based series (Evans et al,
1991a). The early age at onset of medulloblastoma in Gorlin
syndrome and the more recent evidence that chromosome 9q is
involved in at least a portion of medulloblastoma cases (Albrecht
et al, 1994; Schofield et al, 1995) suggests that the Gorlin gene
acts as a tumour suppressor. There is further evidence from basal
cell carcinomas and an ovarian fibroma substantiating this
suggested role of the Gorlin gene (Gailani et al, 1992). However,
there is no published evidence of specific loss of the wild-type
allele in medulloblastoma. The recent identification of the Gorlin
gene (Hahn et al, 1996; Johnson et al, 1996) should soon shed
more light on its role in tumorigenesis. The diagnosis of two new
Gorlin syndrome families from our original series has prompted us
to update the risk figures for Gorlin syndrome and medulloblas-
toma and to investigate whether the wild-type allele is lost in
medulloblastomas from our Gorlin syndrome patients.
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PATIENTS AND METHODS
We have previously reported on the follow-up data from 173
consecutive cases of medulloblastoma occurring in the North
Western Regional Health Authority area (population 4 001 000) of
England (Evans et al, 1991a). Since that report, two further
patients with Gorlin syndrome have been identified. Patient 1
(93/102, family 1; Figure 2) was diagnosed aged 23 months as
having a cerebellar medulloblastoma, and a diagnosis of Gorlin
syndrome was made at age 10 years after development ofmultiple
Table 1 Diagnostic criteria for naevoid basal cell carcinoma syndrome
(a diagnosis can be made when two major or one major and two minor
criteria are fulfilled)
Majorcriteria
(1) Multiple (> 2) basal cell carcinomas or one under 30 years, or > 10 basal
cell naevi
(2) Any odontogenic keratocyst (proven on histology) or polyostotic bone
cyst
(3) Palmar or plantar pits (three or more)
(4) Ectopic calcification: lamellar or early (< 20 years) falx calcification
(5) Family history of NBCCS
Minor criteria
(1) Congenital skeletal anomaly: bifid, fused, splayed or missing rib, or bifid,
wedged or fused vertebra
(2) OFC > 97th centile, with frontal bossing
(3) Cardiac or ovarian fibroma
(4) Medulloblastoma
(5) Lymphomesenteric cysts
(6) Congenital malformation: cleft lip and or palate, polydactyly, eye anomaly
(cataract, coloboma, microphthalmia)
OFC, occipito-frontal head circumference
141142 R Cowan etal
Table 2 LOH studies in tumours and a cataract from three families with
Gorlin syndrome
Family 1 Family 2 Family 3
93/102a 94/136a 94/Ca 95/104a
BCCb Medb Lensb BCC BCC Med Med
D9S12 NL NL NL NL NL NL NL
D9S197 NL NL NI NI Loss Loss NL
D9S196 NL NL NL NL Loss Loss NI
D9S287 NL NL NL NL Imb Loss NL
D9S180 NL NL NL NL NL NL NL
D9S127 NL NL NL NL NL NL NL
aPatient number. bTissue type. NL, no loss; NI, not informative; Imb,
imbalance (visually judged difference in band intensity to the constitutional
material); Med, medulloblastoma.
pigmented naevi on the skin surrounding his spinal irradiation.
Patient 2 (95/104; Table 2) was similarly diagnosed with Gorlin
syndrome at age 10 years after treatment for medulloblastoma
aged 17 months. Neither patient had extensive skin lesions at the
time of the previous study and the only anomaly on the skeletal
surveys was a spina bifida occulta at SI (patient 1). Nonetheless,
at 10 years ofage, both patients had extensive falx calcification on
skull radiography, and a family survey including radiological
investigation revealed a number of individuals affected with
Gorlin syndrome in each family (Table 1 and Figure 1). The diag-
nosis was made largely on the basis ofradiographic findings, such
as bifid ribs and dense falx calcification, and all affected relatives
fulfilled the diagnostic criteria in Table 1. Thus, 94/G, 94/722 and
94/136 in family 1 (Figure 2) were clearly affected clinically/radi-
ologically and the mother and sister of patient 2 (pedigree not
shown) were also found to be affected (linkage data suggest that
the mother was a new mutation; data not shown). However, no
individual in either family had presented with jaw cysts or basal
cell carcinomas before investigation. A basal cell carcinoma was
removed from the lower eyelid in the maternal grandfather of
patient 1 after being seen for genetic counselling (DNA analysis
below). The initial skin lesions removed from both medulloblas-
toma patients were reported as compound naevi, however subse-
quent lesions from case 1 have been basal cell carcinomas. On the
basis of the two newly diagnosed cases, risk calculations for
medulloblastoma and Gorlin syndrome have been reappraised.
Molecular analysis
Peripheral blood was taken from patients in tubes containing 0.5 M
EDTA. Fresh lens material was collected at the time of surgery
from 94/136 (Figure 2) and was frozen in liquid nitrogen. This was
later ground down and DNA was extracted from the resultant lens
epithelial cells. It was not known what proportion of these cells
were 'normal' lens epithelial cells as microdissection was not
possible. Tumour was provided from formalin-fixed, paraffin-
embedded blocks obtained from the pathology department at
Royal Manchester Children's Hospital. Ten-micron sections of
tumour-only material were cut from blocks of medulloblastoma
and BCCs from affected individuals. In all cases DNA was
extracted using standard procedures.
Linkage analysis
Microsatellite analysis was performed using sequence-tagged sites
(STSs) mapped to 9q22.3-q31 (Famdon et al, 1994). The
following STSs were analysed: D9S12, D9S196, D9S197,
D9S287, D9S180 and D9S127. Polymerase chain reactions
(PCRs) were performed in 50-gl reactions containing a final
concentration of lx PCR buffer (Boehringer; magnesium chloride
1.5 mmol), 100 ,UM of each dNTP (Boehringer), 1 ,UM of each
primer and 1 U of Taq DNA polymerase. Amplification was
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Figure 1 Pedigrees for families 1 (A) and 2 (B). This shows co-segregation of the haplotype cfjno with disease in family 1 and cdjmq in family 2. Allele orders
are for probes D9S12, D9S197, D9S196, D9S287 and D9S180. Individual 94/723 who has no diagnostic features of Gorlin syndrome has inherited the high-risk
haplotype
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Figure 2 Microsatellite analysis for marker D9S197 in family 2. The
medulloblastoma sample in the right-hand lane has lost the wild-type allele f
(inherited from the unaffected mother 94/B)
performed in an automated thermocycler (Grant Autogene).
Following an initial denaturation step at 94°C for 2 min, reactions
were cycled 32 times under the following conditions: 94°C for
1 min of denaturation, 55°C for 1 min (D9S196, D9S197,
D9S127) or 58°C for 1 min (D9S287, D9S180) of annealing and
72°C for 1 min. PCR products were visualized on 2% agarose gels
stained with ethidium bromide. Microsatellite analysis was carried
out as described (Orphanos et al, 1993). DNA from blood was run
for affected and unaffected individuals from each family. Allele
sizes were scored, and phase (parental origin and orderofmarkers)
was established.
LOH studies
Microsatellite analysis was carried out as above. Tumour/normal
products were run in adjacent tracks and relative allele intensities
were compared visually. If an allele was lost then its parental
origin was determined from the linkage analysis.
RESULTS
Including the two previously established cases ofGorlin syndrome
occurring in the consecutive medulloblastoma series of 173
patients (Evans et al, 1991a), the new diagnoses above give a
minimum incidence of 4 out of 173 (2.3%). Along with the previ-
ously reported case of a child with Gorlin syndrome dying from a
presumed medulloblastoma (Evans et al, 1991a), the actual
proportion of cases due to Gorlin syndrome is likely to be in
excess of 3%. All four of the proven cases occurred at less than 3
years of age, representing 4 out of 67 (6%) cases diagnosed aged
less than 5 years and 3 out of 28 (10.7%) of those diagnosed less
than 2 years of age.
All four tumours were of the desmoplastic subtype of medul-
loblastoma on pathology review.
Linkage analysis
Linkage analysis for one of the two newly diagnosed Gorlin
syndrome families is shown in Figure 1. Family 1 containing
patient 1 (93/102) showed inheritance ofthe haplotype cfjno in the
affected grandfather, mother andproband. However, the co-triplets
of the mother (94/772, 94/723) showed no external features
suggestive of Gorlin syndrome. The female triplet did have dense
falx calcification on skull radiography, thus fulfilling diagnostic
criteria (Evans et al, 1993), however her brother had no radiolog-
ical or clinical manifestations of the condition at the age of 43
years. His head circumference and height were on the 97th
percentile. Linkage analysis in the other families was consistent
with clinical findings.
Loss of heterozygosity at 9q21
The results of loss of heterozygosity (LOH) studies are shown in
Table 2. No loss was found in the tumours from family 1 or 3, or
from the lens DNA. However, a narrow region ofloss was found in
both the medulloblastoma and BCC from the proband in family 2.
Both tumours showed loss of D9S196, D9S197 and D9S287 but
retention of D9S180. This places the Gorlin syndrome gene
centromeric of D9S180. The alleles lost in each case were those
inherited from the patients unaffected mother. Loss of this wild-
type allele in the medulloblastoma is shown in Figure 2.
DISCUSSION
Although until fairly recently it was thought that the great majority
of genes predisposing to familial forms of cancer were tumour
suppressors (Knudson, 1989), recent evidence has shown that
oncogenes in multiple endocrine neoplasia type 2 (Mulligan et al,
1993) and DNA repair genes in hereditary non-polyposis colon
cancer (HNPCC) (Fishel et al, 1993; Bronner et al, 1994) are
significant contributors to hereditary cancer and to at least a
proportion of sporadic cases. There is no evidence for LOH as a
mechanism for cancer progression with oncogenes. While there is
some recent evidence for LOH at the site of the HNPCC genes
(Hemminki et al, 1994), this is generally absent (Lindblom et al,
1993). Previous studies of LOH in familial breast and ovarian
cancer (Smith et al, 1992) have confirmed the role ofBRCAJ as a
tumour-suppressor gene before it was cloned. Likewise, our study
has provided strong evidence that the Gorlin syndrome gene acts
in this way in medulloblastoma as well as confirming this forbasal
cell carcinoma. However, as there is some disputed clinical
evidence for radiation sensitivity in Gorlin syndrome, with the
appearance ofmultiple skin cancers post irradiation (Strong 1977;
Cutler et al, 1979; Hawkins et al, 1979), and there is some prelim-
inary evidence for increased sensitivity to radiation ofGorlin cells
in vitro (see Featherstone et al, 1983; Nagasawa et al, 1984), the
possibility that the Gorlin gene is in some way involved in moni-
toring DNA processing cannot be entirely discounted. The recent
evidence of loss of wild type at the MLHI locus in HNPCC
(Hemminki et al, 1994) and the failure of heterozygosity of
mismatch repair gene mutations to affect DNA repair (Parsons
et al, 1993) shows that LOH is not completely the preserve of
classical tumour-suppressor genes.
Although LOH has previously been shown in two informative
medulloblastomas from Gorlin patients (Schofield et al, 1995), loss
of the normal wild-type allele has not been shown before now. It
would appear that the Gorlin locus is involved in a small subset of
medulloblastoma in which there is a desmoplastic phenotype. The
presence of this phenotype in our Gorlin patients is further confir-
mation ofthis. The failure to detect LOH in the other two medullo-
blastomas tested may represent a second hit involving a smaller
deletion or mutation of the wild-type allele. The second hit may
also not affect all the tumour tissue as it may be preceded by other
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mutational events. Contamination with normal cells is unlikely as
sections were reviewed and contained tumour-only material. It is
likely that oldercases and non-desmoplastic tumours are less likely
to have involvement of the Gorlin syndrome locus. Nonetheless,
the report of Schofield et al (1995) would tend to refute the earlier
report ofAlbrecht et al (1994), downplaying the role of the Gorlin
syndrome locus in sporadic disease. Since the cloning ofthe Gorlin
gene (Hahn et al, 1996; Johnson et al, 1996), there are already
reports of second hits in BCCs involving missense mutations
(Unden et al, 1996). However, more detailed mapping ofdeletions
and mutations in medulloblastoma is still awaited. Until then, the
true importance ofthe Gorlin syndrome gene in sporadic medullo-
blastoma will remain conjecture. Recently LOH has been shown to
be the mechanism for the development of the typical jaw cysts in
Gorlin syndrome (Levanet et al, 1996). We were unable to confirm
this as a mechanism for the development of a cataract in an
affected family member. The mechanism by which the Gorlin gene
acts as a tumour suppressor is still not fully elucidated, but it does
involve transcriptional repression of genes encoding members of
the transforming growth factor beta and wnt protein families and is
involved in the signal transduction pathway of sonic hedgehog
(Hahn et al, 1996; Johnson et al, 1996). The gene that is homolo-
gous to the Drosophila genepatchedencodes a putative transmem-
brane protein. It is unlikely that this gene is involved in any way in
DNA repair.
It has previously been thought that the penetrance for Gorlin
syndrome is near complete, with the majority of affected individ-
uals developing basal cell carcinomas andjaw cysts (Gorlin, 1987;
Evans et al, 1993; Shanley et al, 1994). The two families that we
have identified through an index case with medulloblastoma have
clear evidence of Gorlin syndrome, but none of the family
members had presented with a Gorlin complication. Therefore,
enquiries into family history would not have been helpful in diag-
nosing our two new cases at presentation of their medulloblast-
oma. Although one patient had a spina bifida occulta on skeletal
survey, this is a common feature in the general population. Indeed,
neither patient had falx calcification at presentation, although this
did develop by 10 years of age. It is doubtful therefore that these
patients could have been diagnosed at presentation unless the
parents were examined in detail, including a skeletal survey.
Diagnosis in a very young child is difficult in the absence of
congenital skeletal changes, such as bifid ribs, unless there is a
known affected parent (Table 1). This is because of the age-
dependent nature of so many of the features (jaw cysts, basal cell
carcinomas, falx calcification). It is still possible that there is
underascertainment of Gorlin syndrome patients in childhood
medulloblastoma, and the true incidence may be even higher.
Family 1 presented a particular problem in that there was one male
family member aged 43 years without any clear diagnostic feature,
only a head circumference in keeping with his size. It is possible
that he represents a double recombinant or that this family is not
linked to the Gorlin locus (no LOH was found in the three tumours
from this family). There are no reports of families unlinked to 9q
(Farmdon et al, 1994; Povey et al, 1994). It seems more likely that
he carries the mutant allele but remains non-penetrant. This case
could, therefore, have implications forclinical assessment in fami-
lies and may mean that certain mutations in the Gorlin gene
produce a less complete phenotype. Gorlin syndrome may, there-
fore, be much more common than is generally accepted.
In view of the high incidence of Gorlin syndrome in children
aged under 2 years (10%) with medulloblastoma, it is probably
advisable to examine the parents of these early-onset cases in
detail. In addition, patients with desmoplastic tumours should also
be considered strong candidates for having Gorlin syndrome. In
view ofthe known development of multiple basal cell carcinomas
in the irradiation field (Strong 1977; Evans et al, 1991b), some
attempt at limiting skin exposure should be made (Evans et al,
1991b). However, the length of time to onset of developing basal
cell naevi or carcinoma may be considerably longer than the 3
years post irradiation previously cited (Strong et al, 1977). As all
four patients with Gorlin syndrome have had long-term survival,
with only the fifth probable patient dying within 10 years, it is
likely that this represents a real prognostic indicator as has been
previously suggested (Gorlin, 1990). As it is known that desmo-
plastic tumours have a more favourable prognosis, it is possible
that the survival advantage is related to the histology of the
tumours that Gorlin syndrome sufferers develop. Nonetheless, the
absence of a clear family history in the two new cases does raise
the possibility that some of the deceased patients may also have
had Gorlin syndrome.
Our report is consistent with the localization ofthe Gorlin gene
to a region centromeric to D9S180, in keeping with a previously
reported recombinant in an unaffected individual (Farndon et al,
1994). As disease status may not always be unequivocal clinically,
as in our family 1, this report lends further weight to the previous
linkage data.
CONCLUSION
There is now strong evidence that the Gorlin syndrome gene acts
as a tumour-suppressor gene in childhood medulloblastoma. Thus,
the incidence ofthis tumour in Gorlin syndrome is about 5%, and
as many as 10% of medulloblastomas occurring in children under
2 years ofage are due to Gorlin syndrome. Efforts should be made
to establish whether or not early-onset cases of medulloblastoma
are due to Gorlin syndrome as this has implications for treatment
and prognosis.
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